Iovance Biotherapeutics, Inc. (IOVA) SEC Filing 8-K Material Event for the period ending Friday, October 19, 2018

Iovance Biotherapeutics, Inc.

CIK: 1425205 Ticker: IOVA

View differences made from one to another to evaluate Iovance Biotherapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Iovance Biotherapeutics, Inc..


Assess how Iovance Biotherapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Iovance Biotherapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Iovance Biotherapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: IOVA
CIK: 1425205
Form Type: 8-K Corporate News
Accession Number: 0001144204-18-055365
Submitted to the SEC: Thu Oct 25 2018 4:45:28 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Friday, October 19, 2018
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: